NIKKEI 225
27,584.08-57.75(-0.21%)HANG SENG
26,426.55+231.73(+0.88%)CRUDE OIL
68.47-2.09(-2.96%)GOLD FUTURES
1,813.60-0.50(-0.03%)DOW
34,792.67-323.73(-0.92%)BTC-GBP
28,657.33+849.67(+3.06%)
Transgene SA (0OCQ.L)
| Previous close | 2.3000 |
| Open | 2.2651 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2648 - 2.2651 |
| 52-week range | 2.2648 - 2.2651 |
| Volume | 6,835 |
| Avg. volume | N/A |
| Market cap | 141.262M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2021
STRASBOURG, France, July 06, 2021--Regulatory News: Under the liquidity contract entrusted by Transgene (Paris:TNG) to Natixis Oddo BHF SCA, as of June 30, 2021, the following resources were managed through the liquidity account:
- Business Wire
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
STRASBOURG, France, June 28, 2021--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that the first UK patient has been enrolled in the Phase I clinical trial of TG4050, Transgene’s innovative individualized cancer immunotherapy, currently being evaluated in HPV-negative head and neck cancer patients. TG4050 is a therapeutic vaccine based on Transgene’s myvac® technology platform, which lev
- Business Wire
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
STRASBOURG, France, June 24, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient has been enrolled in a randomized, controlled Phase II study evaluating the combination of TG4001 with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023).
